for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tenax Therapeutics Inc

TENX.OQ

Latest Trade

1.21USD

Change

-0.08(-5.84%)

Volume

8,407

Today's Range

1.21

 - 

1.33

52 Week Range

1.10

 - 

2.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.29
Open
1.33
Volume
8,407
3M AVG Volume
0.82
Today's High
1.33
Today's Low
1.21
52 Week High
2.79
52 Week Low
1.10
Shares Out (MIL)
6.74
Market Cap (MIL)
8.16
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2019 Tenax Therapeutics Inc Earnings Release

Latest Developments

More

Tenax Therapeutics Provides Update On Phase 2 Pulmonary Hypertension Clinical Trial

Tenax Therapeutics Provides Update On Phase 2 Pulmonary Hypertension Clinical Trial

Tenax Therapeutics Provides Clinical Development Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tenax Therapeutics Inc

Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

Contact Info

1 Copley Pkwy Ste 490

+1.919.8064414

http://www.tenaxthera.com/

Executive Leadership

Ronald Ray Blanck

Independent Chairman of the Board

Michael B. Jebsen

President, Chief Financial Officer

Anthony DiTonno

Chief Executive Officer, Director

Douglas Hay

Executive Vice President - Regulatory Affairs

Doug Randall

Executive Vice President - Business and Commercial Operations

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-7.600

2017

-6.270

2018

-4.360

2019(E)

-1.555
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.25
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-135.27
Return on Equity (TTM)
-118.44

Latest News

Latest News

BRIEF-Tenax Therapeutics Files For Mixed Shelf Of Up To $75 Mln

* TENAX THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $75 MILLION – SEC FILING Source text: (http://bit.ly/2rK4oYR) Further company coverage:

BRIEF-Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies

* TENAX THERAPEUTICS ANNOUNCES PLAN TO DEVELOP LEVOSIMENDAN FOR A PULMONARY HYPERTENSION INDICATION WITH NO FDA APPROVED THERAPIES

BRIEF-Asterias Biotherapeutics completes enrollment and dosing of a cohort of an early-stage study

* Asterias Biotherapeutics completes enrollment and dosing of scistar study's ais-a 20 million cell cohort

BRIEF-Tenax meets with FDA to discuss positive mortality data and potential levosimendan NDA submission

* Tenax meets with FDA to discuss positive mortality data and potential levosimendan NDA submission

BRIEF-Tenax hires Ladenburg Thalmann to review strategic options

* Tenax Therapeutics announces review of strategic alternatives and business update

BRIEF-Tenax Therapeutics had $21.9 mln in cash as of December 31, 2016

* Tenax Therapeutics announces year-end 2016 financial results and provides corporate update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up